← Back to Search

All Participants for Type 2 Diabetes (EXPET Trial)

Led By Bret Goodpaster, PhD
Research Sponsored by Translational Research Institute for Metabolism and Diabetes, Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 30-65 years
Type 2 diabetes mellitus determined by self-report or by a fasting glucose >126mg/dl
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

EXPET Trial Summary

This trial looks at how exercise affects insulin resistance in people with Type 2 Diabetes.

Who is the study for?
This trial is for adults aged 30-65 with Type 2 Diabetes who are sedentary, have a BMI of 25-45 kg/m2, and haven't had significant weight changes recently. They must not be on more than two glucose-lowering medications or insulin and should be free from major diseases or conditions that could interfere with the study.Check my eligibility
What is being tested?
The study tests how exercise affects insulin resistance in people with Type 2 Diabetes by using PET imaging, muscle and fat biopsies, and measuring maximum ATP production. Participants will undergo an exercise regimen to see if it improves their condition.See study design
What are the potential side effects?
Potential side effects may include discomfort at biopsy sites, reactions to the contrast agent used in PET imaging (like mild itching or rash), risks associated with exercising such as muscle strain, and possible bruising from the clamp procedure.

EXPET Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am between 30 and 65 years old.
I have type 2 diabetes.

EXPET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Individual steps of muscle glucose uptake (post-exercise)
Individual steps of muscle glucose uptake (pre-exercise)

EXPET Trial Design

1Treatment groups
Experimental Treatment
Group I: All ParticipantsExperimental Treatment6 Interventions
First Studied
Drug Approval Stage
How many patients have taken this drug
Adipose Tissue Biopsy
Muscle Biopsy
Completed Phase 1

Find a Location

Who is running the clinical trial?

Translational Research Institute for Metabolism and Diabetes, FloridaLead Sponsor
40 Previous Clinical Trials
3,585 Total Patients Enrolled
AdventHealth Translational Research InstituteLead Sponsor
48 Previous Clinical Trials
20,169 Total Patients Enrolled
Bret Goodpaster, PhDPrincipal InvestigatorScientific Director | Senior Investigator
5 Previous Clinical Trials
468 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the target demographic for this research younger than 40 years old?

"This research study is open to people in their thirties up until those of retirement age."

Answered by AI

Is there an opportunity for individuals to enlist in this clinical trial at present?

"According to clinicaltrials.gov, this clinical trial is actively enlisting participants. It was first publicized on March 30th 2021 and has been modified most recently on August 2nd 2022."

Answered by AI

How many participants have been welcomed into this clinical experiment?

"Indeed, clinicaltrials.gov confirms that this research is actively looking for volunteers. This experiment was initially made available on March 30th 2021 and the details were last updated on August 2nd 2022. 12 patients are needed at one medical site to complete the trial."

Answered by AI

Am I eligible to join the clinical trial?

"The prerequisites for this clinical trial stipulate that applicants must have type 2 diabetes mellitus and be aged between 30 to 65. The total number of participants being recruited is 12."

Answered by AI
~1 spots leftby Aug 2024